UroGen Pharma Presents New Data From A Long-Term Follow-Up Study Published In The Journal Of Urology Online To The OLYMPUS Trial Show Median Duration Of Response Of 4-Years In Patients Who Achieved A Complete Response With JELMYTO
UroGen Pharma Presents New Data From A Long-Term Follow-Up Study Published In The Journal Of Urology Online To The OLYMPUS Trial Show Median Duration Of Response Of 4-Years In Patients Who Achieved A Complete Response With JELMYTO
The Study Results are Published in the Journal of Urology Online
研究結果發表在《在線泌尿外科雜誌》上
UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today highlights results from a long-term follow-up study with JELMYTO (mitomycin) for pyelocalyceal solution, which is FDA approved for the treatment of low-grade, upper tract urothelial cancer (LG-UTUC) in adult patients. Among patients from the OLYMPUS trial who achieved a complete response after primary chemoablation with JELMYTO (n=41, 20 of whom entered the long-term follow-up study), the median duration of response was 47.8 months (median follow-up 28.1 months [95% CI 13.1, 57.5]). The study results are published online in the Journal of Urology.
致力於開發和商業化治療尿路上皮癌和特殊癌症的新型解決方案的生物技術公司UroGen Pharma Ltd.（納斯達克股票代碼：URGN）今天重點介紹了使用JELMYTO（絲裂黴素）進行腎盂溶液的長期隨訪研究的結果，該溶液已獲美國食品藥品管理局批准用於治療成人患者的低度上路尿路上皮癌（LG-UTUC）。在奧林巴斯試驗中使用JELMYTO進行初次化療後獲得完全緩解的患者中（n=41，其中20人進入長期隨訪研究），中位緩解持續時間爲47.8個月（中位隨訪28.1個月 [95% CI 13.1，57.5]）。研究結果在線發表在《泌尿外科雜誌》上。
